Inicio › Linfoma no Hodgkin › Massachusetts › Boston
Ensayos clínicos de Linfoma no Hodgkin en Boston, MA
26 estudios para Linfoma no Hodgkin buscan participantes en centros de Boston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
ReclutandoFase 2
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
ReclutandoFase 1/2
- Research Site, Boston
- Research Site, Boston
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
ReclutandoFase 1/2
- Dana-Farber Cancer Institute, Boston
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
ReclutandoFase 2
- Boston Medical Center, Boston
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
ReclutandoFase 2
- Dana-Farber Cancer Institute, Boston
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
ReclutandoFase 1
- Tufts Medical Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
ReclutandoFase 1/2
- Dana-Farber Cancer Institute, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
ReclutandoEstudio observacional
- Dana Farber Cancer Institute, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
ReclutandoFase 1Se aceptan voluntarios sanos
- Brigham and Women's Hospital, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
ReclutandoFase 2
- Dana Farber Cancer Institute, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ReclutandoEstudio observacional
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
ReclutandoEstudio observacional
- Dana-Farber Cancer Institute, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Reclutando
- Dana Farber Cancer Institute, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
ReclutandoFase 1
- Massachusetts General Hospital, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
ReclutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
ReclutandoFase 2Se aceptan voluntarios sanos
- DFCI/BWH Brigham and Women's Hospital, Boston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
ReclutandoFase 4
- Dana-Farber Cancer Institute, Boston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
ReclutandoFase 4
- Dana-Farber Cancer Institute, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
ReclutandoFase 1
- Beth Israel Deaconess Medical Center, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
ReclutandoFase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ensayos de Linfoma no Hodgkin en otras ciudades
- Houston, TX31 estudios
- New York City, NY31 estudios
- Nashville, TN21 estudios
- Philadelphia, PA20 estudios
- Baldwin Park, CA19 estudios
- Washington, DC18 estudios
- Milwaukee, WI18 estudios
- Atlanta, GA18 estudios
- Chicago, IL18 estudios
- Columbus, OH18 estudios
- Dallas, TX17 estudios
- Seattle, WA16 estudios
Otros estudios en Boston
- Cáncer de seno112 estudios
- Cáncer de pulmón de células no pequeñas90 estudios
- Cáncer (todos los tipos)85 estudios
- Cáncer metastásico63 estudios
- Cáncer del colon y del recto63 estudios
- Cáncer de pulmón62 estudios
- Cáncer de ovario61 estudios
- Cáncer de próstata59 estudios
- Depresión52 estudios
- Cáncer de endometrio50 estudios
- Fallo cardíaco44 estudios
- Leucemia mielógena aguda44 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.